Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a precision oncology company, released financial results for the first quarter of 2023.
Q1 2023 Financial Highlights
-
The company reported a net loss of approximately $17.7 million, or a net loss per diluted share of $4.24, for the three months ended March 31, 2023, compared to a net loss of approximately $9.4 million, or a net loss per diluted share of $2.26, for the same period in 2022.
-
Operating expenses increased by $8.8 million to approximately $17.3 million for the three months ended March 31, …